Market is saying either they don't believe Mayne can commercialize the product as successfully as Mayne have said they will, or that the erosion in the rest of the business will counteract any success... or... both. They need to get some sales on the board for E4, minimise erosion in H2, get Nuvaring finally approved, and maybe even do another deal on menopause. And in the meantime, Scott and Investor Relations need to start communicating with the god damn market. The silence is deafening. They do a terrible job of selling confidence to the market. FDA have just approved a product that Mayne estimate has peak net sales in excess of half their current full business annual sales, but the market doesn't care? Unbelievable
MYX Price at posting:
36.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)